due to NASH, a form of non-alcoholic fatty liver disease (NAFLD). In the 182-patient study, patients were treated with one of two doses of the FGF21 mimic or placebo - given as a once-weekly ...

Altered PPARA signaling in NASH contributes to messed-up fat processing and liver inflammation. Importantly, FGF19 and FGF21 are essential targets for drugs that regulate bile acids and energy in ...

The results of a phase 2b ENLIVEN trial of FGF21 analogue pegozafermin showed it was able to reduce scarring (fibrosis) in the liver of NASH patients at more than three times the rate of a placebo ...

Madrigal is likely to face competition as more NASH assets get approved, especially from the more efficacious FGF21 analogue drug class in more severe fibrotic NASH patient populations.

Fibroblast growth factor 21 (FGF21) analogs significantly improve fibrosis and resolve metabolic dysfunction-associated steatohepatitis (MASH) without progression, showing promise for non ...

The results demonstrated a statistically significant fibrosis benefit, which Smith regards as transformational for the field and supportive of ETNB's FGF21 analog, pegozafermin, in NASH.

There are three different FGF21 receptor types ... The disease formerly known as NASH (non-alcoholic steatohepatitis) was recently renamed in the medical literature to the more descriptive ...

Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.